AxoGen, Inc. (NASDAQ:AXGN) Q4 2022 Earnings Call Transcript

Karen Zaderej: Yes. So we haven’t given any updates on a description of the product. I can tell you it won’t be available this year. We’ll complete the BLA and then be talking with the FDA about the second generation and – on Avance. And then we are also working on some concepts for a third-generation Avance with the idea that we would like to have a third-generation Avance 12 years from now.

Dave Turkaly: Thank you.

Operator: Thank you. At this time, we’ve reached end of our question-and-answer session. I’ll hand the floor back to Karen Zaderej for closing remarks.

Karen Zaderej: Thank you, Rob, and I’d like to thank the AxoGen team who remain very committed to our mission of improving the quality of life for patients with peripheral nerve injuries. We’re happy with the progress we’ve made towards our goal this year, and we remain focused on ensuring our long-term success. I want to thank everyone for joining us this morning. Thank you, and have a great day.

Operator: This will conclude today’s conference. Thank you for your participation. You may now disconnect your lines at this time.